Validación española de la escala de evaluación de los síntomas negativos-16 (NSA-16) en pacientes con esquizofrenia

  1. Garcia-Alvarez, L. 125
  2. Garcia-Portilla, M.P. 1256
  3. Saiz, P.A. 1256
  4. Fonseca-Pedrero, E. 23
  5. Bobes-Bascaran, M.T. 2
  6. Gomar, J. 247
  7. Muñiz, J. 1
  8. Bobes, J. 1256
  1. 1 Universidad de Oviedo
    info

    Universidad de Oviedo

    Oviedo, España

    ROR https://ror.org/006gksa02

  2. 2 Centro de Investigacion Biomedica en Red de Salud Mental
    info

    Centro de Investigacion Biomedica en Red de Salud Mental

    Madrid, España

    ROR https://ror.org/009byq155

  3. 3 Universidad de La Rioja
    info

    Universidad de La Rioja

    Logroño, España

    ROR https://ror.org/0553yr311

  4. 4 FIDMAG Hermanas Hospitalarias Research Foundation, Sant Boi de Llobregat, Spain
  5. 5 Instituto Universitario de Neurociencias del Principado de Asturias (INEUROPA), Oviedo, Spain
  6. 6 Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain
  7. 7 Feinstein Institute for Medical Research
    info

    Feinstein Institute for Medical Research

    Manhasset, Estados Unidos

    ROR https://ror.org/05dnene97

Mostrar afiliaciones +
Revista:
Revista de Psiquiatría y Salud Mental

ISSN: 1888-9891

Año de publicación: 2018

Volumen: 11

Número: 3

Páginas: 169-175

Tipo: Artículo

beta Ver similares en nube de resultados
DOI: 10.1016/J.RPSM.2018.03.001 SCOPUS: 2-s2.0-85044992767 GOOGLE SCHOLAR

Otras publicaciones en: Revista de Psiquiatría y Salud Mental

Repositorio institucional: lockAcceso abierto Editor lockAcceso abierto Editor

Objetivos de desarrollo sostenible

Resumen

Introduction: Negative symptoms are prevalent in schizophrenia and associated with a poorer outcome. Validated newer psychometric instruments could contribute to better assessment and improved treatment of negative symptoms. The Negative Symptom Assessment-16 (NSA-16) has been shown to have strong psychometric properties, but there is a need for validation in non-English languages. This study aimed to examine the psychometric properties of a Spanish version of the NSA-16 (Sp-NSA-16). Material and method: Observational, cross-sectional validation study in a sample of 123 outpatients with schizophrenia. Assessments: NSA-16, PANSS, HDRS, CGI-SCH and PSP. Results: The results indicate appropriate psychometric properties, high internal consistency (Cronbach's alpha = 0.86), convergent validity (PANSS negative scale, PANSS Marder Negative Factor and CGI-negative symptoms r values between 0.81 and 0.94) and divergent validity (PANSS positive scale and the HDRS r values between 0.10 and 0.34). In addition, the NSA-16 also exhibited discriminant validity (ROC curve = 0.97, 95% CI = 0.94 to 1.00; 94.3% sensitivity and 83.3% specificity). Conclusions: The Sp-NSA-16 is reliable and valid for measuring negative symptoms in patients with schizophrenia. This provides Spanish clinicians with a new tool for clinical practice and research. However, it is necessary to provide further information about its inter-rater reliability. © 2018 SEP y SEPB